ArticleJACC. Advances2026
Projected Impact of LDL-C and HbA
Article in JACC. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundU.S. population estimates of atherosclerotic cardiovascular disease (ASCVD) risk reduction from comprehensive cardiometabolic risk factor control remain limited among patients with ASCVD and diabetes mellitus (DM).
objectivesThe objective of the study was to predict 3-year reduction in composite ASCVD event risk and number of preventable events associated with achieving guideline-based targets for low-density lipoprotein cholesterol (LDL-C) and/or hemoglobin A1c (HbA
methodsUsing National Health and Nutrition Examination Survey 2011 to 2020 data weighted to the U.S. population, we identified adults with ASCVD and DM with uncontrolled LDL-C (≥70 mg/dL) and HbA
resultsWe included 131 participants, representing 1.73 million U.S. adults. Predicted 3-year relative risk reductions were 18.0% and 23.7%, corresponding to 38,200 and 50,100 predicted preventable events, with LDL-C lowering to 70 mg/dL or 55 mg/dL, respectively; 29.3%, corresponding to 62,100 events, with additional control of HbA1c; and 37.0%, corresponding to 66,500 events, with additional BMI reductions.
conclusionsIn U.S. adults with ASCVD and DM, LDL-C control provides the greatest projected reduction in ASCVD risk among individual risk factors, whereas comprehensive control of LDL-C, glycemia, and weight produces the greatest overall projected benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.